NCT01413906View on ClinicalTrials.gov

Phase 1 Multiple Ascending Dose Study of BMS-833923 (XL139) in Subjects With Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions

Cancer

Interventions

DRUG

BMS-833923 (XL139)

Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria

Trial Locations (1)

2778577

Local Institution, Kashiwa-shi